Mary Caffrey

Following former President Joe Biden's diagnosis with metastatic prostate cancer, news coverage has focused on his lack of prostate-specific antigen (PSA) screening over the past decade.

Drugs first approved to treat diabetes, which later became a top sellers to aid weight loss, are associated with reduced risk of obesity-related cancer.

Assistance from artificial intelligence can potenially increase the number of patients eligible for treatment for HER2-low breast cancers.

ASCO and Google Cloud unveil an AI tool that streamlines access to clinical guidelines, enhancing decision-making for oncologists in patient care.

SCAN Group takes ownership of an integrated care delivery organization, to expand its impact on the lives of vulnerable seniors.

According to news reports, Biden's cancer is aggressive and has reached the bones.

Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center, discusses some of the recent trends in cancer detection, screenings, and resource utilization in community oncology.

Pieter Sonneveld, MD, PhD, professor of hematology and chair of the Erasmus MC Cancer Institute in Rotterdam, Netherlands, discussed the continued use of subcutaneous daratumumab following initial treatment, as well as the changing landscape of multiple myeloma treatment.

The National Comprehensive Cancer Network (NCCN) policy summit highlighted the need for improved communication between oncology and primary care to enhance cancer survivor outcomes and care transitions.

Pieter Sonneveld, MD, PhD, chair of the Erasmus MC Cancer Institute, discussed the findings of a study modeling long-term progression-free survival (PFS) in patients with multiple myeloma (MM) treated with a daratumumab quadruplet regimen.

KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, as highlighted at the 2025 meeting of the American Association for Cancer Research (AACR).

IO Biotech's first-in-class vaccine performs double duty, killing cancer cells and enhancing the tumor microenvironment. A phase 3 trial is on track to release results this fall.

Results presented on Tuesday at the American Association for Cancer Research annual meeting include data on the combined use of tissue and liquid biopsy, as well as a framework for evaluating multicancer early detection testing.

Prior studies have shown that women may absorb cancer therapies differently than men, but this study focused on the fallout on patients' physical activity and quality of life.

From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ground.

Results could give patients with HER2-mutated non–small cell lung cancer (NSCLC) an oral therapy option.

The session follows the American Association for Cancer Research's (AACR) prior call to action against executive orders that would harm the National Institutes of Health.

Dostarlimab effectively eliminates the need for surgery in patients with advanced mismatch repair–deficient tumors in renal cancer, enhancing quality of life.

New York Oncology and Hematology becomes the 27th practice in OneOncology.

A program cochair said the agenda was designed to get attendees "out of their comfort zone." The Amercian Association for Cancer Research annual meeting runs April 25-30, with the key presentations coming Sunday through Tuesday.

These advances are designed to improve uptake of biomarker-driven cancer care and reduce treatment delays.

Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.

The California-based entities plan to offer new Medicare Advantage (MA) products in select counties by this fall.

This article appears in the April issue of Evidence-Based Oncology.